Morgan P, Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today. 2012;17:419–24.
Musuamba F, Manolis E, Holford N, et al. Advanced methods for dose and regimen finding during drug development: summary of the EMA/EFPIA workshop on dose finding (London 4–5 December 2014). CPT Pharmacometrics Syst Pharmacol. 2017;6:418–29.
Zandvliet AS, Schellens JH, Beijnen JH, Huitema AD. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. Clin Pharmacokinet. 2008;47:487–513.
van der Graaf PH, Benson N. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm Res. 2011;28:1460–4.
Abbott L, Michor F. Mathematical models of targeted cancer therapy. Brit J Cancer. 2006;95:6603310.
Ribba B, Holford N, Magni P, Trocóniz I, Gueorguieva I, Girard P, et al. A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. CPT Pharmacometrics Syst Pharmacol. 2014;3:1–10.
Altrock PM, Liu LL, Michor F. The mathematics of cancer: integrating quantitative models. Nat Rev Cancer. 2015;15:730–45.
Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J. Cancer: a systems biology disease. Biosystems. 2006;83:81–90.
Bachmann J, Raue A, Schilling M, Becker V, Timmer J, Klingmüller U. Predictive mathematical models of cancer signalling pathways. J Intern Med. 2012;271:155–65.
Kolch W, Halasz M, Granovskaya M, Kholodenko BN. The dynamic control of signal transduction networks in cancer cells. Nat Rev Cancer. 2015;15:515–27.
Araujo R, McElwain D. A history of the study of solid tumour growth: the contribution of mathematical modelling. B Math Biol. 2003;66:1039.
Rejniak KA, Anderson AR. Hybrid models of tumor growth. Wiley Interdiscip Rev Syst Biology Medicine. 2011;3:115–25.
Hasselt J, Eijkelenburg N, Beijnen JH, Schellens J, Huitema A. Optimizing drug development of anti-cancer drugs in children using modelling and simulation. Brit J Clin Pharmaco. 2013;76:30–47.
Carrara L, Lavezzi S, Borella E, Nicolao G, Magni P, Poggesi I. Current mathematical models for cancer drug discovery. Expert Opin Drug Dis. 2017;12:785–99.
Powathil GG, Swat M, Chaplain M. Systems oncology: towards patient-specific treatment regimes informed by multiscale mathematical modelling. Semin Cancer Biol. 2015;30:13–20.
Barbolosi D, Ciccolini J, Lacarelle B, Barlési F, André N. Computational oncology — mathematical modelling of drug regimens for precision medicine. Nat Rev Clin Oncol. 2015;13:242–54.
Dua P, Dua V, Pistikopoulos EN. Optimal delivery of chemotherapeutic agents in cancer. Comput Chem Eng. 2008;32:99–107.
Zhu J, Liu R, Jiang Z, Wang P, Yao Y, Shen Z. Optimization of drug regimen in chemotherapy based on semi-mechanistic model for myelosuppression. J Biomed Inform. 2015;57:20–7.
Iliadis A, Barbolosi D. Optimizing drug regimens in cancer chemotherapy by an efficacy–toxicity mathematical model. Comput Biomed Res. 2000;33:211–26.
Alam HMA, Algoul S, Majumader MAA, Al-Mamun MA, Sexton G, Phillips R. Multi-objective multi-drug scheduling schemes for cell cycle specific cancer treatment. Comput Chem Eng. 2013;58:14–32.
Irurzun-Arana I, Janda A, Ardanza-Trevijano S, Trocóniz IF. Optimal dynamic control approach in a multi-objective therapeutic scenario: application to drug delivery in the treatment of prostate cancer. PLoS Comput Biol. 2018;14:e1006087.
Fister RK, Panetta J. Optimal control applied to cell-cycle-specific cancer chemotherapy. SIAM J Appl Math. 2000;60(1059):1072.
Schulthess P, Post TM, Yates J, van der Graaf PH. Frequency-domain response analysis for quantitative systems pharmacology models. CPT Pharmacometrics Syst Pharmacol. 2018;7:111–23.
Mitchell A, Wei P, Lim WA. Oscillatory stress stimulation uncovers an Achilles’ heel of the yeast MAPK signaling network. Science. 2015;350(1379):1383.
Schulthess P, van Wijk RC, Krekels EH, Yates JW, Spaink HP, van der Graaf PH. Outside-in systems pharmacology combines innovative computational methods with high-throughput whole vertebrate studies. CPT Pharmacometrics Syst Pharmacol. 2018;7:285–7.
Gardner SN. Cell cycle phase-specific chemotherapy: computation methods for guiding treatment. Cell Cycle. 2002;1:369–74.
Dibrov BF, Zhabotinsky AM, Neyfakh YA, Orlova MP, Churikova LI. Optimal scheduling for cell synchronization by cycle-phase-specific blockers. Math Biosci. 1983;66:167–85.
Dibrov BF, Zhabotinsky AM, Neyfakh YA, Orlova MP, Churikova LI. Mathematical model of cancer chemotherapy. Periodic schedules of phase-specific cytotoxic-agent administration increasing the selectivity of therapy. Math Biosci. 1985;73:1–31.
Agur Z, Arnon R, Schechter B. Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs. Math Biosci. 1988;92:1–15.
Bernard S, Bernard B, Lévi F, Herzel H. Tumor growth rate determines the timing of optimal chronomodulated treatment schedules. PLoS Comput Biol. 2010;6:e1000712.
Zhu X, Zhou X, Lewis MT, Xia L, Wong S. Cancer stem cell, niche and EGFR decide tumor development and treatment response: a bio-computational simulation study. J Theor Biol. 2011;269:138–49.
Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002;20:4713–21.
Barbolosi D, Iliadis A. Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK–PD model. Comput Biol Med. 2001;31:157–72.
Hahnfeldt P, Folkman J, Hlatky L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol. 2003;220:545–54.
Benzekry S, Pasquier E, Barbolosi D, Lacarelle B, Barlési F, André N, et al. Metronomic reloaded: theoretical models bringing chemotherapy into the era of precision medicine. Semin Cancer Biol. 2015;35:53–61.
Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol. 2016;13:659–73.
Mpekris F, Baish JW, Stylianopoulos T, Jain RK. Role of vascular normalization in benefit from metronomic chemotherapy. Proc National Acad Sci. 2017;114:1994–9.
Houy N, Grand F. Administration of temozolomide: comparison of conventional and metronomic chemotherapy regimens. J Theor Biol. 2018;446(71):78.
Foo J, Michor F. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput Biol. 2009;5:e1000557.
Foo J, Michor F. Evolution of resistance to anti-cancer therapy during general dosing schedules. J Theor Biol. 2010;263:179–88.
He Q, Zhu J, Dingli D, Foo J, Leder K. Optimized treatment schedules for chronic myeloid leukemia. PLoS Comput Biol. 2016;12:e1005129.
Eigenmann MJ, Frances N, Lavé T, Walz A-C. PKPD modeling of acquired resistance to anti-cancer drug treatment. J Pharmacokinet Pharmacodyn. 2017;44:617–30.
Panetta JC, Adam J. A mathematical model of cycle-specific chemotherapy. Math Comput Model. 1995;22:67–82.
Faivre C, Barbolosi D, Pasquier E, André N. A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens. Cancer Chemoth Pharm. 2013;71:1013–9.
Panetta J, Kirstein MN, Gajjar AJ, Nair G, Fouladi M, Stewart CF. A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. Math Biosci. 2003;186:29–41.
Hoshino-Yoshino A, Kato M, Nakano K, Ishigai M, Kudo T, Ito K. Bridging from preclinical to clinical studies for tyrosine kinase inhibitors based on pharmacokinetics/pharmacodynamics and toxicokinetics/toxicodynamics. Drug Metab Pharmacok. 2011;26:612–20.
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73.
Suleiman A, Frechen S, Scheffler M, Zander T, Nogova L, Kocher M, et al. A modeling and simulation framework for adverse events in erlotinib-treated non-small-cell lung cancer patients. AAPS J. 2015;17:1483–91.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. New Engl J Medicine. 2010;362:2380–8.
Andersen L, Mackey MC. Resonance in periodic chemotherapy: a case study of acute myelogenous leukemia. J Theor Biol. 2001;209:113–30.
D’Onofrio A, Gandolfi A. A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. Math Medicine Biology. 2008;26:63–95.
D’Onofrio A, Gandolfi A (2010) Chemotherapy of vascularised tumours: role of vessel density and the effect of vascular “pruning.” J Theor Biol 264:253–265
Chmielecki J, Foo J, Oxnard GR, et al (2011) Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science translational medicine 3:90ra59 90ra59.
Yu H, Sima C, Feldman D, et al (2016) Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR -mutant lung cancers. Ann Oncol mdw556.
Traina TA, Theodoulou M, Feigin K, Patil S, Tan LK, Edwards C, et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol. 2008;26:1797–802.
Traina TA, Dugan U, Higgins B, Kolinsky K, Theodoulou M, Hudis CA, et al. Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling. Breast Dis. 2010;31:7–18.
Foo J, Chmielecki J, Pao W, Michor F. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. J Thorac Oncol. 2012;7:1583–93.
Sachs JR, Mayawala K, Gadamsetty S, Kang S, de Alwis DP. Optimal dosing for targeted therapies in oncology: drug development cases leading by example. Am Assoc Cancer Res. 2016;22:1318–24.
Ribba B, Boetsch C, Nayak TK, et al (2018) Prediction of the optimal dosing regimen using a mathematical model of tumour uptake for immunocytokine-based cancer immunotherapy. Clin Cancer Res 24:clincanres.2953.2017.
Stein S, Zhao R, Haeno H, Vivanco I, Michor F. Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. PLoS Comput Biol. 2018;14:e1005924.
Mazzocco P, Honnorat J, Ducray F, Ribba B. Increasing the time interval between PCV chemotherapy cycles as a strategy to improve duration of response in low-grade gliomas: results from a model-based clinical trial simulation. Comput Math Method M. 2015;2015:297903.